Siglec-6/CD327 Fc Chimera Protein, Human

浏览次数：7

货号： UA010027

大包装询价

产品介绍引用文献(0) 评论(0)

产品规格

物种

Human
Accession

AAH35359.2
表达序列

Gln16-Val320, with C-terminal Human IgG Fc
表达宿主

HEK293
分子量

75-95 kDa(Reducing)
纯度

＞95%, by SDS-PAGE under reducing conditions
内毒素含量

<0.1EU/μg
标记

Unconjugated
标签

Human Fc Tag
性状

Lyophilized Powder
缓冲体系

PBS, pH7.4
溶解方法

Reconstitute at less than 1 mg/mL according to the size in ultrapure water after rapid centrifugation .
储存条件

· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.

背景介绍

Siglec-6 also called CD327, one of the Sialic acid-binding immunoglobulin-like lectins (Siglecs) and type-1 transmembrane protein. Siglec-6 is predominantly expressed by mast cells, B cells, and a minor AS-type dendritic cell subset. Siglec-6 is an immune-inhibitory CD33-related Siglec and strongly binds to sialylated Tn-structures. As an exception, all Siglecs recognize the carboxyl group of sialic acid, but only Siglec-6 does not require the glycerol side-chain for binding. In cancer, Siglec-6 was recently found to be upregulated in circulating and urinary CD⁸⁺ T-cell of non–muscle-invasive bladder cancer patients, wherein a high level of Siglec-6 was associated with advanced bladder cancer. Additionally, Siglec-6 is prevalently expressed on acute myeloid leukemia blasts and transformed B cells in chronic lymphocytic leukemia. As Siglec-6 mRNA and protein are not expressed in hematopoietic stem cells, they are novel targets for CAR-T cell immunotherapy in chronic lymphocytic leukemia.